CSIMarket
 
Ocuphire Pharma Inc   (OCUP)
 

Ocuphire Pharma Inc reported Revenue of $39.85 millions, in the Dec 31 2022 report

OCUP delivered fourth quarter of 2022 operating surplus of $34.21 millions


Published Mar 31 2023
CSIMarket Team / CSIMarket.com


Dryvax_pd the Major Pharmaceutical Preparations company has seen $39.85 millions, in Revenue in the financial interval ending December 31 2022.




Ocuphire Pharma Inc have achieved net income of $33.941 millions in the financial interval ending December 31 2022 an improvement versus a net shortfall of $-6.313 millions in the similar reporting season a year ago. Ocuphire Pharma Inc also emphasized it's improving profit margins, where net margin rose to 85.17% in financial interval ending December 31 2022, and operating margin edged up to 85.85%.
the Major Pharmaceutical Preparations company realized profitability of $17.89 millions and Revenues of $39.85 millions for the financial year 2022.

Ocuphire Pharma Inc recorded earnings per share of $0.87 compare to $-3.82 in the previous financial year, while Revenue doubled by 6665.7 % from $0.59 millions a year ago.

Ocuphire Pharma Inc is expected to report next financial recent numbers on May 12, 2023.



Ocuphire Pharma Inc's Price to earnings ratio PE

Ocuphire Pharma Inc's Executive Officers



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com